Trial reportWorld journal of gastroenterology2007
Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.
Trial report in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.Gut and liver · 2016Pooled it
- Infusion Reactions to Infliximab in Pediatric Patients with Inflammatory Bowel Disease.Children (Basel, Switzerland) · 2024Review
- Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.EClinicalMedicine · 2023Article
- Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis.ClinicoEconomics and outcomes research : CEOR · 2023Review
- Staging Pouch Surgery in Ulcerative Colitis in the Biological Era.Clinics in colon and rectal surgery · 2022Review
- Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study.Intestinal research · 2021Article
- Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Article
- Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up.Biologics : targets & therapy · 2019Article
- Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis.Intestinal research · 2018Article
- Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.Journal of gastroenterology · 2017Article
- Strategies for Preventing Endoscopic Recurrence of Crohn's Disease 1 Year after Surgery: A Network Meta-Analysis.Gastroenterology research and practice · 2017Review
- Usefulness of sulfasalazine for patients with refractory-ulcerative colits.BMJ open gastroenterology · 2016Article
- Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists.Therapeutics and clinical risk management · 2015Review
- Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.World journal of gastroenterology · 2014Review
- TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.World journal of gastroenterology · 2014Review
- Effectiveness of infliximab after adalimumab failure in Crohn's disease.World journal of gastroenterology · 2012Article
- Current and emerging drugs for the treatment of inflammatory bowel disease.Drug design, development and therapy · 2011Review
- Update on the management of inflammatory bowel disease: specific role of adalimumab.Clinical and experimental gastroenterology · 2011Article
- Recent advances in the management of distal ulcerative colitis.World journal of gastrointestinal pharmacology and therapeutics · 2010Article
- Current directions of biologic therapies in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy of adalimumab induction therapy in patients with ulcerative colitis who previously responded to infliximab and then lost response or became intolerant.
methodsTen patients with ulcerative colitis were enrolled in a 4-wk open-label trial. The patients received a loading dose of 160 mg adalimumab at wk 0 followed by 80 mg at wk 2. The primary efficacy measure was clinical improvement at wk 4, as defined by a decrease in clinical activity index (CAI) of more than 4.
resultsFour of 10 patients (40%) benefited from subsequent adalimumab therapy; one patient achieved remission (CAI<4) and 3 had clinical improvement at wk 4. 6 patients had no response (60%); 2 of 6 (33.3%) subsequently underwent colectomy. This was accompanied by a decrease in median CRP concentration from 16.8 mg/mL at baseline to 3.85 mg/mL at wk 4, excluding two patients who underwent colectomy after two infusions of adalimumab. Among the 6 patients with severe colitis (CAI>12) at baseline, none achieved remission and only one patient had clinical improvement at wk 4.
conclusionThe small advantage of adalimumab in patients with mild to moderate ulcerative colitis and lost response or intolerance to infliximab needs to be confirmed in randomised, double-blind, placebo-controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.